Heldin CH, Rubin K, Pietras K, Östman A. High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806–13.
Article
CAS
PubMed
Google Scholar
Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418–29.
Article
CAS
PubMed
PubMed Central
Google Scholar
Erler JT, Weaver VM. Three-dimensional context regulation of metastasis. Clin Exp Metastasis. 2009;26:35–49.
Article
PubMed
Google Scholar
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457–61.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, Smith BL, Ferrone CR, Hornicek FJ, Boucher Y, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci USA. 2012;109:15101–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994;13:139–68.
Article
CAS
PubMed
Google Scholar
Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509–15.
CAS
PubMed
Google Scholar
Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437–47.
Article
CAS
PubMed
Google Scholar
Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004;14:198–206.
Article
PubMed
Google Scholar
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100–4.
CAS
PubMed
Google Scholar
Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, Wiesmann M, Woodman R, Gallagher N. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem. 2010;18:6977–86.
Article
CAS
PubMed
Google Scholar
Pietras K, Östman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61:2929–34.
CAS
PubMed
Google Scholar
Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin CH, Östman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62:5476–84.
CAS
PubMed
Google Scholar
Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kurizaki T, Nearman J, Paulsson J, Mosley RL, Enke CA, Ostman A. Effect of platelet-derived growth factor receptor-β inhibition with STI571 on radioimmunotherapy. Cancer Res. 2005;65:7824–31.
CAS
PubMed
PubMed Central
Google Scholar
Vlahovic G, Rabbani ZN, Herndon JE 2nd, Dewhirst MW, Vujaskovic Z. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer. 2006;95:1013–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Levick JR. Flow through interstitium and other fibrous matrices. Q J Exp Physiol. 1987;72:409–37.
Article
CAS
PubMed
Google Scholar
Eikenes L, Bruland ØS, Brekken C, Davies Cde L. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 2004;64:4768–73.
Article
CAS
PubMed
Google Scholar
Oldberg Å, Kalamajski S, Salnikov AV, Stuhr L, Mörgelin M, Reed RK, Heldin NE, Rubin K. Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc Natl Acad Sci USA. 2007;104:13966–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gade TP, Buchanan IM, Motley MW, Mazaheri Y, Spees WM, Koutcher JA. Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors. Clin Cancer Res. 2009;15:247–55.
Article
CAS
PubMed
PubMed Central
Google Scholar
Friman T, Gustafsson R, Stuhr LB, Chidiac J, Heldin NE, Reed RK, Oldberg Å, Rubin K. Increased fibrosis and interstitial fluid pressure in two different types of syngeneic murine carcinoma grown in integrin β3-subunit deficient mice. PLoS ONE. 2011;7(3):e34082.
Article
Google Scholar
Torosean S, Flynn B, Axelsson J, Gunn J, Samkoe KS, Hasan T, Doyley MM, Pogue BW. Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure. Nanomedicine. 2013;9:151–8.
Article
CAS
PubMed
Google Scholar
Klosowska-Wardega A, Hasumi Y, Burmakin M, Åhgren A, Stuhr L, Moen I, Reed RK, Rubin K, Hellberg C, Heldin CH. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS ONE. 2009;4(12):e8149.
Article
PubMed
PubMed Central
Google Scholar
Olsson PO, Gustafsson R, In’t Zandt R, Friman T, Maccarana M, Tykesson E, Oldberg Å, Rubin K, Kalamajski S. The tyrosine kinase inhibitor Imatinib augments extracellular fluid exchange and reduces average collagen fibril diameter in experimental carcinoma. Mol Cancer Ther. 2016;15:2455–64.
Article
CAS
PubMed
Google Scholar
Hasumi Y, Klosowska-Wardega A, Furuhashi M, Östman A, Heldin CH, Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer. 2007;121:2606–14.
Article
CAS
PubMed
Google Scholar
Ain KB, Taylor KD. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab. 1994;78:1097–102.
CAS
PubMed
Google Scholar
Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93:4331–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dahlman T, Lammerts E, Wik M, Bergström D, Grimelius L, Westermark K, Rubin K, Heldin NE. Fibrosis in undifferentiated (anaplastic) thyroid carcinomas: evidence for a dual action of tumour cells in collagen type I synthesis. J Pathol. 2000;191:376–86.
Article
CAS
PubMed
Google Scholar
Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC, et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim. 1988;22:195–201.
Article
CAS
PubMed
Google Scholar
Rubin K, Sjöquist M, Gustafsson AM, Isaksson B, Salvessen G, Reed RK. Lowering of tumoral interstitial fluid pressure by prostaglandin E1 is paralleled by an increased uptake of 51Cr-EDTA. Int J Cancer. 2000;86:636–43.
Article
CAS
PubMed
Google Scholar
Berg RA. Determination of 3- and 4-hydroxyproline. Methods Enzymol. 1982;82(Pt A):372–98.
Article
CAS
PubMed
Google Scholar
Karlsson S, Kowanetz K, Sandin A, Persson C, Östman A, Heldin CH, Hellberg C. Loss of T-cell protein tyrosine phosphatase induces recycling of the platelet-derived growth factor (PDGF) β-receptor but not the PDGF α-receptor. Mol Biol Cell. 2006;17:4846–55.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sjöblom T, Shimizu A, O’Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Östman A, Heldin CH. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001;61:5778–83.
PubMed
Google Scholar
Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–76.
Article
CAS
PubMed
Google Scholar
Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908–16.
Article
PubMed
Google Scholar
Maharsy W, Aries A, Mansour O, Komati H, Nemer M. Ageing is a risk factor in imatinib mesylate cardiotoxicity. Eur J Heart Fail. 2014;16:367–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, Laengle U, Ledieu D, Marrer E, Nussher A, et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res. 2010;34:1180–8.
Article
CAS
PubMed
Google Scholar
Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, Hynes J, Patyna S, Jessen BA. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008;106:153–61.
Article
CAS
PubMed
Google Scholar
Nassar I, Pasupati T, Judson JP, Segarra I. Reduced exposure of imatinib after coadministration with acetaminophen in mice. Indian J Pharmacol. 2009;41:167–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935–42.
Article
CAS
PubMed
Google Scholar
Breccia M, Molica M, Alimena G. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. Leuk Res. 2014;38:1392–8.
Article
CAS
PubMed
Google Scholar